A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
Part of paid clinical trials in New York, New York.
- Sponsor
- Weill Medical College of Cornell University
- Study ID
- NCT00161564
- Phase
- PHASE2
- Status
- Withdrawn
Conditions
- Idiopathic Thrombocytopenic Purpura (ITP)
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
Study Details
The purpose of this research study is to compare the efficacy and safety of higher doses of rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine, and Prednisone) in patients with chronic Idiopathic Thrombocytopenic Purpura (ITP who did not respond to or relapsed after standard doses of rituximab.
Key Dates
- Start date
- Feb 29, 2004
- Status verified
- Jul 2018
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Weill Medical College of Cornell University Division of Pediatric Hematology-Oncology | New York | New York | 10021 | - |